Gist-Brocades N.v.

Dsm N.v.

Lambertus C Dorssers

Robert W Van Leen

Yvonne J Vos

Gerard Wagemaker

Maria L Persoon

Biologically active deletion and substitution mutants of hIL-3 are provided. Preferred mutants are those having one or more deletions at the N-terminus (amino acids 1-14) and/or the C-terminus (amino acids 116-133, 120-130 and/or 130-133). Preferred substitution mutants include Cys.sup.16 .fwdarw.Ala.sup.16 and/or Cys.sup.84 .fwdarw.Ala.sup.84, Glu.sup.50 .fwdarw.Lys.sup.50 and Lys.sup.79 .fwdarw.Glu.sup.79. These mutants can be used to formulate pharmaceutical compositions. Also disclosed are antibodies directed against specific epitopes localized between amino acids 29 and 54.

N- and C-terminal truncation and deletion mutants of human interleukin-3

Methods are provided for improved production of hIL-3 either in glycosylated form from mammalian and yeast cells or in unglycosylated form from prokaryotes. Recombinantly produced human IL-3 is purified in a series of steps, initially employing hydrophobic interaction, followed by ion exchange chromatography and gel filtration.

Growing community of inventors

Randwijk, Netherlands

Lambertus C Dorssers